International Journal of Cancer Management

Published by: Kowsar

A Review of Cutaneous Squamous Cell Carcinoma Epidemiology, Diagnosis, and Management

Soodeh Kabir 1 , Chrysalyne D. Schmults 2 and Emily S. Ruiz 2 , *
Authors Information
1 Department of Dermatology, Guilan University of Medical Sciences, Rasht, IR Iran
2 Department of Dermatology, Brigham and Women’s Hospital, Harvard Medical School, Boston, USA
Article information
  • International Journal of Cancer Management: January 2018, 11 (1); e60846
  • Published Online: January 29, 2018
  • Article Type: Review Article
  • Received: August 26, 2017
  • Revised: November 7, 2017
  • Accepted: January 21, 2018
  • DOI: 10.5812/ijcm.60846

To Cite: Kabir S, Schmults C D, Ruiz E S. A Review of Cutaneous Squamous Cell Carcinoma Epidemiology, Diagnosis, and Management, Int J Cancer Manag. 2018 ; 11(1):e60846. doi: 10.5812/ijcm.60846.

Abstract
Copyright © 2018, Cancer Research Center (CRC), Shahid Beheshti University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited
1. Context
2. Evidence Acquisition
3. Results
4. Conclusions
Acknowledgements
Footnotes
References
  • 1. Karia PS. Epidemiology and Outcomes of Cutaneous Squamous Cell Carcinoma. High-Risk Cutaneous Squamous Cell Carcinoma. Berlin Heidelberg: Springer; 2016.
  • 2. Kivisaari A, Kahari VM. Squamous cell carcinoma of the skin: Emerging need for novel biomarkers. World J Clin Oncol. 2013;4(4):85-90. doi: 10.5306/wjco.v4.i4.85. [PubMed: 24926428].
  • 3. Scotto J, Fears TR, Fraumeni JF. Incidence of nonmelanoma skin cancer in the United States. US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Cancer Institute; 1983.
  • 4. Lomas A, Leonardi-Bee J, Bath-Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol. 2012;166(5):1069-80. doi: 10.1111/j.1365-2133.2012.10830.x. [PubMed: 22251204].
  • 5. Omari AK, Khammash MR, Matalka I. Skin cancer trends in northern Jordan. Int J Dermatol. 2006;45(4):384-8. doi: 10.1111/j.1365-4632.2004.02444.x. [PubMed: 16650163].
  • 6. Alzolibani AA, Al Shobaili HA, Robaee AA, Khan A, Haque IU, Rao NS, et al. Clinical and histopathologic characteristics of skin malignancies in Qassim Region, Saudi Arabia. Int J Health Sci (Qassim). 2013;7(1):61-5. [PubMed: 23559906].
  • 7. Al-Maghrabi JA, Al-Ghamdi AS, Elhakeem HA. Pattern of skin cancer in Southwestern Saudi Arabia. Saudi Med J. 2004;25(6):776-9. [PubMed: 15195210].
  • 8. Bahamdan KA, Morad NA. Pattern of malignant skin tumors in Asir region, Saudi Arabia. Ann Saudi Med. 1993;13(5):402-6. [PubMed: 17590717].
  • 9. Razi S, Rafiemanesh H, Ghoncheh M, Khani Y, Salehiniya H. Changing Trends of Types of Skin Cancer in Iran. Asian Pac J Cancer Prev. 2015;16(12):4955-8. [PubMed: 26163621].
  • 10. Rigel DS. Cutaneous ultraviolet exposure and its relationship to the development of skin cancer. J Am Acad Dermatol. 2008;58(5 Suppl 2):S129-32. doi: 10.1016/j.jaad.2007.04.034. [PubMed: 18410798].
  • 11. Brash DE, Rudolph JA, Simon JA, Lin A, McKenna GJ, Baden HP, et al. A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci U S A. 1991;88(22):10124-8. [PubMed: 1946433].
  • 12. de Gruijl FR, van Kranen HJ, Mullenders LH. UV-induced DNA damage, repair, mutations and oncogenic pathways in skin cancer. J Photochem Photobiol B. 2001;63(1-3):19-27. [PubMed: 11684448].
  • 13. Tsai KY, Tsao H. The genetics of skin cancer. Am J Med Genet C Semin Med Genet. 2004;131C(1):82-92. doi: 10.1002/ajmg.c.30037. [PubMed: 15468170].
  • 14. Stratigos A, Garbe C, Lebbe C, Malvehy J, del Marmol V, Pehamberger H, et al. Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline. Eur J Cancer. 2015;51(14):1989-2007. doi: 10.1016/j.ejca.2015.06.110. [PubMed: 26219687].
  • 15. Schmitt J, Seidler A, Diepgen TL, Bauer A. Occupational ultraviolet light exposure increases the risk for the development of cutaneous squamous cell carcinoma: a systematic review and meta-analysis. Br J Dermatol. 2011;164(2):291-307. doi: 10.1111/j.1365-2133.2010.10118.x. [PubMed: 21054335].
  • 16. Wehner MR, Shive ML, Chren MM, Han J, Qureshi AA, Linos E. Indoor tanning and non-melanoma skin cancer: systematic review and meta-analysis. BMJ. 2012;345. e5909. doi: 10.1136/bmj.e5909. [PubMed: 23033409].
  • 17. Stern RS, Puva Follow-Up Study . The risk of squamous cell and basal cell cancer associated with psoralen and ultraviolet A therapy: a 30-year prospective study. J Am Acad Dermatol. 2012;66(4):553-62. doi: 10.1016/j.jaad.2011.04.004. [PubMed: 22264671].
  • 18. Yoshinaga S, Hauptmann M, Sigurdson AJ, Doody MM, Freedman DM, Alexander BH, et al. Nonmelanoma skin cancer in relation to ionizing radiation exposure among U.S. radiologic technologists. Int J Cancer. 2005;115(5):828-34. doi: 10.1002/ijc.20939. [PubMed: 15704092].
  • 19. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med. 2003;348(17):1681-91. doi: 10.1056/NEJMra022137. [PubMed: 12711744].
  • 20. Hoogendijk-van den Akker JM, Harden PN, Hoitsma AJ, Proby CM, Wolterbeek R, Bouwes Bavinck JN, et al. Two-year randomized controlled prospective trial converting treatment of stable renal transplant recipients with cutaneous invasive squamous cell carcinomas to sirolimus. J Clin Oncol. 2013;31(10):1317-23. doi: 10.1200/JCO.2012.45.6376. [PubMed: 23358973].
  • 21. Leblanc KJ, Hughes MP, Sheehan DJ. The role of sirolimus in the prevention of cutaneous squamous cell carcinoma in organ transplant recipients. Dermatol Surg. 2011;37(6):744-9. doi: 10.1111/j.1524-4725.2011.01973..x. [PubMed: 21605234].
  • 22. Karia PS, Azzi JR, Heher EC, Hills VM, Schmults CD. Association of Sirolimus Use With Risk for Skin Cancer in a Mixed-Organ Cohort of Solid-Organ Transplant Recipients With a History of Cancer. JAMA Dermatol. 2016;152(5):533-40. doi: 10.1001/jamadermatol.2015.5548. [PubMed: 26792250].
  • 23. Lim WH, Russ GR, Wong G, Pilmore H, Kanellis J, Chadban SJ. The risk of cancer in kidney transplant recipients may be reduced in those maintained on everolimus and reduced cyclosporine. Kidney Int. 2017;91(4):954-63. doi: 10.1016/j.kint.2016.11.008. [PubMed: 28109543].
  • 24. Campbell SB, Walker R, Tai SS, Jiang Q, Russ GR. Randomized controlled trial of sirolimus for renal transplant recipients at high risk for nonmelanoma skin cancer. Am J Transplant. 2012;12(5):1146-56. doi: 10.1111/j.1600-6143.2012.04004.x. [PubMed: 22420843].
  • 25. Euvrard S, Morelon E, Rostaing L, Goffin E, Brocard A, Tromme I, et al. Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med. 2012;367(4):329-39. doi: 10.1056/NEJMoa1204166. [PubMed: 22830463].
  • 26. Asgari MM, Arron ST, Warton EM, Quesenberry CJ, Weisshaar D. Sirolimus use and risk of cutaneous squamous cell carcinoma (SCC) in solid organ transplant recipients (SOTRs). J Am Acad Dermatol. 2015;73(3):444-50. doi: 10.1016/j.jaad.2015.05.029. [PubMed: 26138646].
  • 27. Jellouli-Elloumi A, Kochbati L, Dhraief S, Ben Romdhane K, Maalej M. [Cancers arising from burn scars: 62 cases]. Ann Dermatol Venereol. 2003;130(4):413-6. [PubMed: 12843850].
  • 28. Love RL, Breidahl AF. Acute squamous cell carcinoma arising within a recent burn scar in a 14-year-old boy. Plast Reconstr Surg. 2000;106(5):1069-71. [PubMed: 11039378].
  • 29. Friedman R, Hanson S, Goldberg LH. Squamous cell carcinoma arising in a Leishmania scar. Dermatol Surg. 2003;29(11):1148-9. [PubMed: 14641345].
  • 30. Guo HR, Yu HS, Hu H, Monson RR. Arsenic in drinking water and skin cancers: cell-type specificity (Taiwan, ROC). Cancer Causes Control. 2001;12(10):909-16. [PubMed: 11808710].
  • 31. Karagas MR, Stukel TA, Morris JS, Tosteson TD, Weiss JE, Spencer SK, et al. Skin cancer risk in relation to toenail arsenic concentrations in a US population-based case-control study. Am J Epidemiol. 2001;153(6):559-65. [PubMed: 11257063].
  • 32. Paradisi A, Waterboer T, Sampogna F, Tabolli S, Simoni S, Pawlita M, et al. Seropositivity for human papillomavirus and incidence of subsequent squamous cell and basal cell carcinomas of the skin in patients with a previous nonmelanoma skin cancer. Br J Dermatol. 2011;165(4):782-91. doi: 10.1111/j.1365-2133.2011.10403.x. [PubMed: 21561438].
  • 33. Iftner A, Klug SJ, Garbe C, Blum A, Stancu A, Wilczynski SP, et al. The prevalence of human papillomavirus genotypes in nonmelanoma skin cancers of nonimmunosuppressed individuals identifies high-risk genital types as possible risk factors. Cancer Res. 2003;63(21):7515-9. [PubMed: 14612553].
  • 34. Pierceall WE, Goldberg LH, Ananthaswamy HN. Presence of human papilloma virus type 16 DNA sequences in human nonmelanoma skin cancers. J Invest Dermatol. 1991;97(5):880-4. [PubMed: 1919051].
  • 35. Holm R, Tanum G, Karlsen F, Nesland JM. Prevalence and physical state of human papillomavirus DNA in anal carcinomas. Mod Pathol. 1994;7(4):449-53. [PubMed: 8066073].
  • 36. Mirabelli CK, Bennett CF, Anderson K, Crooke ST. In vitro and in vivo pharmacologic activities of antisense oligonucleotides. Anticancer Drug Des. 1991;6(6):647-61. [PubMed: 1663361].
  • 37. Arron ST, Ruby JG, Dybbro E, Ganem D, Derisi JL. Transcriptome sequencing demonstrates that human papillomavirus is not active in cutaneous squamous cell carcinoma. J Invest Dermatol. 2011;131(8):1745-53. doi: 10.1038/jid.2011.91. [PubMed: 21490616].
  • 38. Shroyer KR, Brookes CG, Markham NE, Shroyer AL. Detection of human papillomavirus in anorectal squamous cell carcinoma. Correlation with basaloid pattern of differentiation. Am J Clin Pathol. 1995;104(3):299-305. [PubMed: 7677119].
  • 39. Vyas R, Zargar H, Trolio RD, Di Lorenzo G, Autorino R. Squamous cell carcinoma of the scrotum: A look beyond the chimneystacks. World J Clin Cases. 2014;2(11):654-60. doi: 10.12998/wjcc.v2.i11.654. [PubMed: 25405188].
  • 40. Waterhouse JA. Subsequent malignancy in environmental scrotal cancers. Proc R Soc Med. 1977;70(2):111-2. [PubMed: 558614].
  • 41. Henry SA. Occupational cutaneous cancer attributable to certain chemicals in industry. Br Med Bull. 1947;4(5-6):389-401. [PubMed: 20240897].
  • 42. Jaju PD, Ransohoff KJ, Tang JY, Sarin KY. Familial skin cancer syndromes: Increased risk of nonmelanotic skin cancers and extracutaneous tumors. J Am Acad Dermatol. 2016;74(3):437-51. quiz 452-4. doi: 10.1016/j.jaad.2015.08.073. [PubMed: 26892653].
  • 43. Odenbro A, Bellocco R, Boffetta P, Lindelof B, Adami J. Tobacco smoking, snuff dipping and the risk of cutaneous squamous cell carcinoma: a nationwide cohort study in Sweden. Br J Cancer. 2005;92(7):1326-8. doi: 10.1038/sj.bjc.6602475. [PubMed: 15770206].
  • 44. Leonardi-Bee J, Ellison T, Bath-Hextall F. Smoking and the risk of nonmelanoma skin cancer: systematic review and meta-analysis. Arch Dermatol. 2012;148(8):939-46. doi: 10.1001/archdermatol.2012.1374. [PubMed: 22711192].
  • 45. Clayman GL, Lee JJ, Holsinger FC, Zhou X, Duvic M, El-Naggar AK, et al. Mortality risk from squamous cell skin cancer. J Clin Oncol. 2005;23(4):759-65. doi: 10.1200/JCO.2005.02.155. [PubMed: 15681519].
  • 46. Carter JB, Johnson MM, Chua TL, Karia PS, Schmults CD. Outcomes of primary cutaneous squamous cell carcinoma with perineural invasion: an 11-year cohort study. JAMA Dermatol. 2013;149(1):35-41. doi: 10.1001/jamadermatol.2013.746. [PubMed: 23324754].
  • 47. Ross AS, Whalen FM, Elenitsas R, Xu X, Troxel AB, Schmults CD. Diameter of involved nerves predicts outcomes in cutaneous squamous cell carcinoma with perineural invasion: an investigator-blinded retrospective cohort study. Dermatol Surg. 2009;35(12):1859-66. doi: 10.1111/j.1524-4725.2009.01354.x. [PubMed: 19889009].
  • 48. Jennings L, Schmults CD. Management of high-risk cutaneous squamous cell carcinoma. J Clin Aesthet Dermatol. 2010;3(4):39-48. [PubMed: 20725546].
  • 49. Brantsch KD, Meisner C, Schonfisch B, Trilling B, Wehner-Caroli J, Rocken M, et al. Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study. Lancet Oncol. 2008;9(8):713-20. doi: 10.1016/S1470-2045(08)70178-5. [PubMed: 18617440].
  • 50. Breuninger H, Schaumburg-Lever G, Holzschuh J, Horny HP. Desmoplastic squamous cell carcinoma of skin and vermilion surface: a highly malignant subtype of skin cancer. Cancer. 1997;79(5):915-9. [PubMed: 9041153].
  • 51. Compton C, Byrd D, Garcia-Aguilar J, Kurtzman S, Olawaiye A, Washington M, et al. AJCC cancer staging manual. New York: Springer; 2010.
  • 52. Sobin LH, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours. John Wiley & Sons; 2011.
  • 53. Frederick L, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, et al. AJCC cancer staging manual. 1. Springer Science & Business Media; 2002.
  • 54. Lee A, Brierley J, O'Sullivan B. Skin Tumours. In: Brierley J, Gospodarowicz M, Ch W, editors. UICC TNM classification of malignant tumours. Chichester Wiley; 2017. p. 131-50.
  • 55. Brougham ND, Dennett ER, Cameron R, Tan ST. The incidence of metastasis from cutaneous squamous cell carcinoma and the impact of its risk factors. J Surg Oncol. 2012;106(7):811-5. doi: 10.1002/jso.23155. [PubMed: 22592943].
  • 56. Schmults CD, Karia PS, Carter JB, Han J, Qureshi AA. Factors predictive of recurrence and death from cutaneous squamous cell carcinoma: a 10-year, single-institution cohort study. JAMA Dermatol. 2013;149(5):541-7. doi: 10.1001/jamadermatol.2013.2139. [PubMed: 23677079].
  • 57. Rowe DE, Carroll RJ, Day CJ. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection. J Am Acad Dermatol. 1992;26(6):976-90. [PubMed: 1607418].
  • 58. Clark WJ, From L, Bernardino EA, Mihm MC. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res. 1969;29(3):705-27. [PubMed: 5773814].
  • 59. Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg. 1970;172(5):902-8. [PubMed: 5477666].
  • 60. Peat B, Insull P, Ayers R. Risk stratification for metastasis from cutaneous squamous cell carcinoma of the head and neck. ANZ J Surg. 2012;82(4):230-3. doi: 10.1111/j.1445-2197.2011.05994.x. [PubMed: 22510179].
  • 61. Karia PS, Jambusaria-Pahlajani A, Harrington DP, Murphy GF, Qureshi AA, Schmults CD. Evaluation of American Joint Committee on Cancer, International Union Against Cancer, and Brigham and Women's Hospital tumor staging for cutaneous squamous cell carcinoma. J Clin Oncol. 2014;32(4):327-34. doi: 10.1200/JCO.2012.48.5326. [PubMed: 24366933].
  • 62. National Comprehensive Cancer Network Clinical Practice. Guidelines in Oncology: squamous cell skin cancer. Version I. 2016. Available from: http://www.nccn.org/professionals/physician_gls/pdf/squamous.pdf.
  • 63. Williams LS, Mancuso AA, Mendenhall WM. Perineural spread of cutaneous squamous and basal cell carcinoma: CT and MR detection and its impact on patient management and prognosis. Int J Radiat Oncol Biol Phys. 2001;49(4):1061-9. [PubMed: 11240248].
  • 64. Balamucki CJ, DeJesus R, Galloway TJ, Mancuso AA, Amdur RJ, Morris CG, et al. Impact of radiographic findings on for prognosis skin cancer with perineural invasion. Am J Clin Oncol. 2015;38(3):248-51. doi: 10.1097/COC.0b013e3182940ddf. [PubMed: 23648439].
  • 65. Ruiz ES, Karia PS, Morgan FC, Schmults CD. The positive impact of radiologic imaging on high-stage cutaneous squamous cell carcinoma management. J Am Acad Dermatol. 2017;76(2):217-25. doi: 10.1016/j.jaad.2016.08.051. [PubMed: 27707594].
  • 66. Schmitt AR, Brewer JD, Bordeaux JS, Baum CL. Staging for cutaneous squamous cell carcinoma as a predictor of sentinel lymph node biopsy results: meta-analysis of American Joint Committee on Cancer criteria and a proposed alternative system. JAMA Dermatol. 2014;150(1):19-24. doi: 10.1001/jamadermatol.2013.6675. [PubMed: 24226651].
  • 67. Navarrete-Dechent C, Veness MJ, Droppelmann N, Uribe P. High-risk cutaneous squamous cell carcinoma and the emerging role of sentinel lymph node biopsy: A literature review. J Am Acad Dermatol. 2015;73(1):127-37. doi: 10.1016/j.jaad.2015.03.039. [PubMed: 26089049].
  • 68. Krediet JT, Beyer M, Lenz K, Ulrich C, Lange-Asschenfeldt B, Stockfleth E, et al. Sentinel lymph node biopsy and risk factors for predicting metastasis in cutaneous squamous cell carcinoma. Br J Dermatol. 2015;172(4):1029-36. doi: 10.1111/bjd.13508. [PubMed: 25362868].
  • 69. Lansbury L, Bath-Hextall F, Perkins W, Stanton W, Leonardi-Bee J. Interventions for non-metastatic squamous cell carcinoma of the skin: systematic review and pooled analysis of observational studies. BMJ. 2013;347:f6153. doi: 10.1136/bmj.f6153. [PubMed: 24191270].
  • 70. Brodland DG, Zitelli JA. Surgical margins for excision of primary cutaneous squamous cell carcinoma. J Am Acad Dermatol. 1992;27(2 Pt 1):241-8. [PubMed: 1430364].
  • 71. Tan PY, Ek E, Su S, Giorlando F, Dieu T. Incomplete excision of squamous cell carcinoma of the skin: a prospective observational study. Plast Reconstr Surg. 2007;120(4):910-6. doi: 10.1097/01.prs.0000277655.89728.9f. [PubMed: 17805118].
  • 72. Miller SJ. The National Comprehensive Cancer Network (NCCN) guidelines of care for nonmelanoma skin cancers. Dermatol Surg. 2000;26(3):289-92. [PubMed: 10759812].
  • 73. Lovett RD, Perez CA, Shapiro SJ, Garcia DM. External irradiation of epithelial skin cancer. Int J Radiat Oncol Biol Phys. 1990;19(2):235-42. [PubMed: 2394605].
  • 74. Ritprajak P, Azuma M. Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma. Oral Oncol. 2015;51(3):221-8. doi: 10.1016/j.oraloncology.2014.11.014. [PubMed: 25500094].
  • 75. Chang AL, Kim J, Luciano R, Sullivan-Chang L, Colevas AD. A Case Report of Unresectable Cutaneous Squamous Cell Carcinoma Responsive to Pembrolizumab, a Programmed Cell Death Protein 1 Inhibitor. JAMA Dermatol. 2016;152(1):106-8. doi: 10.1001/jamadermatol.2015.2705. [PubMed: 26422398].
  • 76. Borradori L, Sutton B, Shayesteh P, Daniels GA. Rescue therapy with anti-programmed cell death protein 1 inhibitors of advanced cutaneous squamous cell carcinoma and basosquamous carcinoma: preliminary experience in five cases. Br J Dermatol. 2016;175(6):1382-6. doi: 10.1111/bjd.14642. [PubMed: 27059424].
  • 77. Muranushi C, Olsen CM, Pandeya N, Green AC. Aspirin and nonsteroidal anti-inflammatory drugs can prevent cutaneous squamous cell carcinoma: a systematic review and meta-analysis. J Invest Dermatol. 2015;135(4):975-83. doi: 10.1038/jid.2014.531. [PubMed: 25521453].
  • 78. Asgari MM, Chren MM, Warton EM, Friedman GD, White E. Association between nonsteroidal anti-inflammatory drug use and cutaneous squamous cell carcinoma. Arch Dermatol. 2010;146(4):388-95. doi: 10.1001/archdermatol.2009.374. [PubMed: 20157019].
  • 79. Elmets CA, Viner JL, Pentland AP, Cantrell W, Lin HY, Bailey H, et al. Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst. 2010;102(24):1835-44. doi: 10.1093/jnci/djq442. [PubMed: 21115882].
  • 80. Surjana D, Halliday GM, Damian DL. Nicotinamide enhances repair of ultraviolet radiation-induced DNA damage in human keratinocytes and ex vivo skin. Carcinogenesis. 2013;34(5):1144-9. doi: 10.1093/carcin/bgt017. [PubMed: 23349012].
  • 81. Chen AC, Martin AJ, Choy B, Fernandez-Penas P, Dalziell RA, McKenzie CA, et al. A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention. N Engl J Med. 2015;373(17):1618-26. doi: 10.1056/NEJMoa1506197. [PubMed: 26488693].
  • 82. Chen AC, Martin AJ, Dalziell RA, McKenzie CA, Lowe PM, Eris JM, et al. A phase II randomized controlled trial of nicotinamide for skin cancer chemoprevention in renal transplant recipients. Br J Dermatol. 2016;175(5):1073-5. doi: 10.1111/bjd.14662. [PubMed: 27061568].
  • 83. Kadakia KC, Barton DL, Loprinzi CL, Sloan JA, Otley CC, Diekmann BB, et al. Randomized controlled trial of acitretin versus placebo in patients at high-risk for basal cell or squamous cell carcinoma of the skin (North Central Cancer Treatment Group Study 969251). Cancer. 2012;118(8):2128-37. doi: 10.1002/cncr.26374. [PubMed: 21882176].
  • 84. Chen K, Craig JC, Shumack S. Oral retinoids for the prevention of skin cancers in solid organ transplant recipients: a systematic review of randomized controlled trials. Br J Dermatol. 2005;152(3):518-23. doi: 10.1111/j.1365-2133.2005.06347.x. [PubMed: 15787821].
  • 85. Haberle SJ, Rimoin L, Trakatelli MG, Zwald F. Management of Patients with Multiple SCCs/Field Cancerization. High-Risk Cutaneous Squamous Cell Carcinoma. Springer; 2016.
  • 86. Endrizzi B, Ahmed RL, Ray T, Dudek A, Lee P. Capecitabine to reduce nonmelanoma skin carcinoma burden in solid organ transplant recipients. Dermatol Surg. 2013;39(4):634-45. doi: 10.1111/dsu.12049. [PubMed: 23379978].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments